News & Updates

Empagliflozin plus GLP-1RA prevents hospitalization, death in adults with T2D
Empagliflozin plus GLP-1RA prevents hospitalization, death in adults with T2D
17 Sep 2024 byStephen Padilla

Patients with type 2 diabetes (T2D) who initiated treatment with empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), and a glucagon-like peptide-1 receptor agonist (GLP-1RA) show reduced hospitalization for heart failure (HHF) and all-cause mortality risks relative to those treated with empagliflozin and dipeptidyl peptidase-4 inhibitors (DPP-4i), reports a study presented at EASD 2024.

Empagliflozin plus GLP-1RA prevents hospitalization, death in adults with T2D
17 Sep 2024
GLP-1RA prevents glaucoma development in T2D patients
GLP-1RA prevents glaucoma development in T2D patients
17 Sep 2024
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
15 Sep 2024
Diabetes, insulin use up risk of death, cardiac events in AF patients
Diabetes, insulin use up risk of death, cardiac events in AF patients
14 Sep 2024